Moderna, Inc.: Virus Diseases trials

The registry lists 30 Virus Diseases studies with Moderna, Inc. as lead sponsor. 2 are open to participants now and 12 have results posted.

Phase 1 5Phase 2 12Phase 3 11Phase 4 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeNot yet recruitingNCT07808697Phase 2
• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsRecruitingNCT06585241Phase 4
• A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusCompletedNCT06097299Phase 2Results posted
• A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgeCompletedNCT06097273Phase 3Results posted
• A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of AgeCompletedNCT06060457Phase 3Results posted
• Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsCompletedNCT05827978Phase 3Results posted
• A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsCompletedNCT05827926Phase 1/2Results posted
• A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19CompletedNCT05815498Phase 3Results posted
• Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in InfantsTerminatedNCT05584202Phase 2Results posted
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeCompletedNCT05330975Phase 3Results posted
• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine BoostersCompletedNCT05137236Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeCompletedNCT05127434Phase 2/3Results posted
• A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19CompletedNCT04649151Phase 2/3Results posted
• Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy AdultsCompletedNCT04232280Phase 2Results posted
• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsActive, not recruitingNCT07496450Phase 3
• A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeCompletedNCT07117487Phase 3
• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsCompletedNCT07089706Phase 4
• Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGEActive, not recruitingNCT06333704
• A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)Active, not recruitingNCT06189053
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersCompletedNCT06143046Phase 2
• Post-marketing Safety of Elasomeran/Davesomeran and AndusomeranCompletedNCT06130345
• A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 VaccineCompletedNCT06113692
• A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsCompletedNCT06067230Phase 3
• A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy AdultsCompletedNCT05972174Phase 1/2
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsActive, not recruitingNCT05831111Phase 1
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Active, not recruitingNCT05683457Phase 2
• A Study of Modified mRNA Vaccines in Healthy AdultsCompletedNCT05397223Phase 1
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeTerminatedNCT05085366Phase 3
• A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineCompletedNCT04975893Phase 2
• A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-SeropositiveCompletedNCT04528719Phase 1